Chemotherapy dose reduction and delay in clinical practice. evaluating the risk to patient outcome in adjuvant chemotherapy for breast cancer.

[1]  D A Berry,et al.  Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. , 1998, Journal of the National Cancer Institute.

[2]  D. Tu,et al.  Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  J. Silber,et al.  First-cycle blood counts and subsequent neutropenia, dose reduction, or delay in early-stage breast cancer therapy. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  D. Smink,et al.  Modeling the cost-effectiveness of granulocyte colony-stimulating factor use in early-stage breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  P. Wingo,et al.  Cancer statistics, 1997 , 1997, CA: a cancer journal for clinicians.

[6]  R. Collins,et al.  Ovarian ablation in early breast cancer: overview of the randomised trials , 1996, The Lancet.

[7]  B. F. Cole,et al.  Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival , 1996, The Lancet.

[8]  G. Bonadonna,et al.  Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. , 1995, The New England journal of medicine.

[9]  L. Norton,et al.  Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. , 1994, The New England journal of medicine.

[10]  R. Gelber,et al.  Understanding adjuvant chemotherapy for breast cancer. , 1994, New England Journal of Medicine.

[11]  Jack Cuzick,et al.  Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women , 1988 .

[12]  W. Hryniuk,et al.  The importance of dose intensity in chemotherapy of metastatic breast cancer. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.